A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

被引:94
作者
Li, Huafang [2 ]
Rui, Qing [1 ]
Ning, Xiaoping [3 ]
Xu, Haiyan [3 ]
Gu, Niufan [2 ]
机构
[1] Xian Janssen Pharmaceut Ltd, CNS, Med Affairs, Beijing 100025, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
Long-acting injectable; Paliperidone palmitate; PANSS; Risperidone; Schizophrenia; SAFETY; EFFICACY; SCALE;
D O I
10.1016/j.pnpbp.2011.02.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia. Eligible Chinese adults (N = 452) with schizophrenia were randomized (1:1) to either PP (N = 229; deltoid injections on day 1 [150 mg eq.] and day 8 [100 mg eq.]; then once-monthly deltoid or gluteal injections, flexibly dosed [50, 100, or 150 mg eq.]). or RIS-LAI (N = 223; once-biweekly gluteal injections, flexibly dosed [25, 37.5 or 50 mg]). RIS-LAI-treated patients received oral risperidone supplementation (1-6 mg/day) at initiation and with RIS-LAI dose increases. Mean (SD) Positive and Negative Syndrome Scale (PANSS) total score at baseline was 83.2 (12.44). Mean (SD) change from baseline to endpoint in PANSS total scores (primary efficacy measure) was: -23.6 (16.28) for PP group and -26.9 (15.43) for RIS-LAI group. PP was noninferior to RIS-LAI (least squares mean difference [95% CI]: -2.3 [-5.20; 0.63]; predetermined non-inferiority margin: -5.5). Mean (SD) change from baseline to endpoint in Clinical Global Impression-Severity scale score was: -1.5 (1.24; PP group), -1.7 (1.16; RIS-LAI group) and in Personal and Social Performance Scale scores was: 16.8 (14.76; PP group), 18.6 (13.92; RIS-LAI group). The incidence of treatment-emergent adverse events (TEAEs) was similar between the two groups (73% [PP]; 75% [RIS-LAI]). The most common TEAEs were akathisia, tremor, and insomnia. The study demonstrated the noninferiority of PP (50-150 mg eq., flexibly dosed, without oral paliperidone supplementation) to risperidone-LAI (25-50 mg, flexibly dosed, with oral risperidone supplementation) for the treatment of acute schizophrenia in adult Chinese patients. PP injections were generally tolerable, and no new safety signals were detected in this population. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1002 / 1008
页数:7
相关论文
共 24 条
  • [1] A RATING-SCALE FOR DRUG-INDUCED AKATHISIA
    BARNES, TRE
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 : 672 - 676
  • [2] Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication
    Citrome, L.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (02) : 216 - 239
  • [3] FLEISCHHACKER W, 2008, ANN M AM COLL NEUR D
  • [4] Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study
    Gopal, Srihari
    Hough, David W.
    Xu, Haiyan
    Lull, Julia M.
    Gassmann-Mayer, Cristiana
    Remmerie, Bart M.
    Eerdekens, Marielle H.
    Brown, David W.
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2010, 25 (05) : 247 - 256
  • [5] GUY, 1976, CGI S CLIN GLOBAL IM
  • [6] Guy W, 1976, AIMS ABNORMAL INVOLU
  • [7] Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia
    Hough, David
    Lindenmayer, Jean-Pierre
    Gopal, Srihari
    Melkote, Rama
    Lim, Pilar
    Herben, Virginie
    Yuen, Eric
    Eerdekens, Marielle
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2009, 33 (06) : 1022 - 1031
  • [8] *INVEGA SUSTENNA, INVEGA SUSTENNA PRES
  • [9] Janicak Philip G, 2007, Neuropsychiatr Dis Treat, V3, P869
  • [10] Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic
    Kane, JM
    Eerdekens, M
    Lindenmayer, JP
    Keith, SJ
    Lesem, M
    Karcher, K
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (06) : 1125 - 1132